Dr. Garon Discusses Pegilodecakin Plus a PD-1 Inhibitor in NSCLC

Edward B. Garon, MD
Published: Wednesday, Jun 27, 2018



Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the combination of pegilodecakin (AM0010) and a PD-1 inhibitor in patients with advanced non–small cell lung cancer (NSCLC).

Findings from an early phase study presented at the 2018 ASCO Annual Meeting showed that combining pegilodecakin with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate of 41% in patients with advanced NSCLC. Partial responses were observed in 11 of the 27 evaluable patients at a median follow-up of 27 months.

Garon says that these responses have been fairly durable, which is encouraging. Additionally, the progression-free survival (PFS) was favorable when compared to historical controls. The median overall survival was 32.2 months for patients who received pegilodecakin plus pembrolizumab, with a median PFS of 11 months.
SELECTED
LANGUAGE


Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the combination of pegilodecakin (AM0010) and a PD-1 inhibitor in patients with advanced non–small cell lung cancer (NSCLC).

Findings from an early phase study presented at the 2018 ASCO Annual Meeting showed that combining pegilodecakin with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate of 41% in patients with advanced NSCLC. Partial responses were observed in 11 of the 27 evaluable patients at a median follow-up of 27 months.

Garon says that these responses have been fairly durable, which is encouraging. Additionally, the progression-free survival (PFS) was favorable when compared to historical controls. The median overall survival was 32.2 months for patients who received pegilodecakin plus pembrolizumab, with a median PFS of 11 months.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x